Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06849544 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

A Phase 2 study of Prostate Cancer Metastatic Disease and Prostate Cancer Surgery, sponsored by Clinton Bahler.

Recruiting
Registry status
Phase 2
Development phase
22
Enrollment target
3
Study locations

NCT06849544: Recruiting Phase 2 study of Prostate Cancer Metastatic Disease and Prostate Cancer Surgery, sponsored by Clinton Bahler.

NCT06849544 is a Phase 2 study of Prostate Cancer Metastatic Disease and Prostate Cancer Surgery that is actively recruiting participants, run by Clinton Bahler. The registered enrollment target is 22 participants, below the 51-participant average among 5 other Prostate Cancer Metastatic Disease trials with a reported enrollment target (57% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06849544, a Phase 2 study of Prostate Cancer Metastatic Disease and Prostate Cancer Surgery, is actively recruiting participants, sponsored by Clinton Bahler.

RECRUITING
Registry status
Phase 2
Development phase
22 participants
Enrollment target
3
Study locations

Study Summary

This study is being done to compare how well Zopocianine (OTL78) in combination with Near InfraRed (NIR) fluorescent imaging may improve the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer.

Primary Outcome

1. Histologically confirmed cancer in residual non-nodal soft tissue resected solely because of "NIR only" detection as suspicious following prostatectomy. 2. One or more resected NIR- positive lymph nodes that contain metastatic disease as confirmed by pathology.

Interventions

  • DRUG 0.03mg/kg ZOPOCIANINE given day of surgery
  • DRUG 0.06mg/kg ZOPOCIANINE given day of surgery
  • DRUG 0.03mg/kg ZOPOCIANINE given day prior to surgery
  • DRUG 0.06mg/kg ZOPOCIANINE given days prior to surgery

Study Locations (3)

Indiana

  • Indiana University Health North Hospital - Carmel
  • Indiana University Health Methodist Hospital - Indianapolis
  • Indiana University School of Medicine - Indianapolis

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2025-04-02
Est. Completion 2026-06
Phase Phase 2
Clinton Bahler

2 total trials

What NCT06849544 shows while recruiting

NCT06849544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 51-participant average among 5 other Prostate Cancer Metastatic Disease trials with a reported enrollment target (57% lower).

The record links to 2 conditions, with Prostate Cancer Metastatic Disease appearing as the primary indexed condition, and to 4 interventions - of which 0.03mg/kg ZOPOCIANINE given day of surgery is the first listed.

NCT06849544 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT06849544 about?

NCT06849544 is a clinical study titled "Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection". This study is being done to compare how well Zopocianine (OTL78) in combination with Near InfraRed (NIR) fluorescent imaging may improve the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prosta...

What is the current status of trial NCT06849544?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2025-04-02. Estimated completion is 2026-06.

What conditions does trial NCT06849544 study?

This clinical trial studies the following conditions: Prostate Cancer Metastatic Disease, Prostate Cancer Surgery.

What interventions are being tested in trial NCT06849544?

The interventions under investigation include: 0.03mg/kg ZOPOCIANINE given day of surgery (DRUG), 0.06mg/kg ZOPOCIANINE given day of surgery (DRUG), 0.03mg/kg ZOPOCIANINE given day prior to surgery (DRUG), 0.06mg/kg ZOPOCIANINE given days prior to surgery (DRUG).

Who is sponsoring clinical trial NCT06849544?

This trial is sponsored by Clinton Bahler, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06849544 being conducted?

This trial has 3 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer Metastatic Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06849544, the US trial registry maintained by the National Library of Medicine. NCT06849544 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.